Ningxia Medical University, Yinchuan, Ningxia 750004, China.
Key Laboratory of Ningxia Minority Medicine Modernization, Ministry of Education (Ningxia Medical University), Yinchuan 750004, China.
Oxid Med Cell Longev. 2023 Jan 5;2023:1117431. doi: 10.1155/2023/1117431. eCollection 2023.
Colon cancer is a relatively common malignant tumor of the digestive tract. Currently, most colon cancers originate from adenoma carcinogenesis. By screening various licorice flavonoids with anticancer effects, we found that glabridin (GBN) has a prominent anticolon cancer effect. First, we initially explored whether GBN can inhibit proliferation, migration, and invasion and induce apoptosis in SW480 and SW620 cells. Next, we exploited reverse virtual and proteomics technologies to screen out closely related target pathways on the basis of a drug and target database. At the same time, we constructed the structure of the GBN target pathway in colon cancer. We predicted that GBN can regulate the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of the rapamycin pathway (mTOR) pathway to fight colon cancer. Finally, through Western blot analysis and qRT-PCR, we verified that the expression levels of the PI3K, AKT, and mTOR proteins and genes in this pathway were significantly reduced after GBN administration. In short, the promising discovery of the anticolon cancer mechanism of GBN provides a reliable experimental basis for subsequent new drug development.
结肠癌是一种较为常见的消化道恶性肿瘤。目前,大多数结肠癌起源于腺瘤癌变。通过对具有抗癌作用的各种甘草类黄酮进行筛选,我们发现甘草素(GBN)具有显著的抗结肠癌作用。首先,我们初步探索了 GBN 是否可以抑制 SW480 和 SW620 细胞的增殖、迁移和侵袭,并诱导其凋亡。接下来,我们利用反向虚拟和蛋白质组学技术,在药物和靶点数据库的基础上筛选出密切相关的靶点通路。同时,我们构建了结肠癌中 GBN 靶通路的结构。我们预测 GBN 可以调节磷脂酰肌醇 3-激酶(PI3K)-蛋白激酶 B(AKT)-雷帕霉素靶蛋白(mTOR)通路来对抗结肠癌。最后,通过 Western blot 分析和 qRT-PCR,我们验证了 GBN 给药后该通路中 PI3K、AKT 和 mTOR 蛋白和基因的表达水平显著降低。总之,GBN 抗结肠癌机制的这一有前景的发现为后续新药开发提供了可靠的实验依据。